For patients with advanced melanoma and a BRAF mutation, additional treatments targeting this mutation have been approved, such as vemurafenib (plus cobimetinib), dabrafenib (plus trametinib), and encorafenib plus binimetinib. The gene discussed is BRAF; the disease is melanoma.